admin, Author at FarmaMondo

FarmaMondo announces the establishment of FarmaMondo JAPAC hub, in Singapore

May 6, 2021April 15, 2021

The FarmaMondo Group announces the establishment of FarmaMondo Pte, a fully owned subsidiary in Singapore. FarmaMondo Pte Singapore will further serve the Group’s development strategy

FarmaMondo innovative therapies

November 16, 2021April 6, 2021

HEAD OF CLINICAL SERVICES – QATAR – DOHA

March 1, 2021

I like to thank FARMAMONDO TEAM for the exceptional response to my inquiry. Your responsiveness and compassion are clear indication of what FarmaMondo represents and the ethos that you all live by. I have personally dealt with many people in my professional life but the attentiveness that you have provided me is something that I will never forget. You are an exemplary representative of FarmaMondo that many companies should try to emulate.

Sarepta Therapeutics and FarmaMondo announce an agreement to exclusively manage access of eteplirsen and golodirsen in Russia

May 10, 2021December 27, 2020

December 2020 – FarmaMondo SA announced an exclusive distribution of eteplirsen and golodirsen for certain patients with Duchenne muscular dystrophy (DMD) in Russia. FarmaMondo SA,

Dompe’ farmaceutici and the FarmaMondo Group: exclusive agreement to distribute oxervate™ in Russia and other CIS countries

May 6, 2021November 10, 2020

November 2020 – Dompé farmaceutici Spa and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner

FarmaMondo new website is now LIVE!

May 6, 2021June 19, 2020

FarmaMondo is pleased to announce the launch of its brand new website! After months of hard work and dedication, we are delighted to officially announce

Zion Medical appoints the FarmaMondo Group to support global named patient access to its novel therapy Gammora™

February 15, 2022June 5, 2020

FarmaMondo and Zion Medical, an Israel startup pharma developer, signed today an agreement to establish a MAP for their novel drug Gammora. The product is

FarmaMondo to exclusively manage access to Metreleptin (Myalept®) by Amryt Pharma for patients with lipodystrophy in CIS (excluding Russia)

April 1, 2021June 1, 2020

Amryt Pharma (www.amrytpharma.com/) has appointed FarmaMondo, the world’s leader in paid-access to unlicensed medicines, to exclusively manage the access of its innovative therapy Metreleptin (FDA/EMA approval under

EUSA and FarmaMondo Group establishes an Emergency Managed Access Program to allow Healthcare Providers to access Siltuximab (Sylvant©) for off label treatment of acute patients of COVID-19

April 1, 2021April 14, 2020

While the world fights through COVID19 pandemic EUSA and Papa Giovani Hospital in Italy had initiated an observational study (SISCO trial – https://clinicaltrials.gov/ct2/show/NCT04322188?term=SISCO&draw=2&rank=1) on Siltuximab

Cookie	Duration	Description
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Analytics" category .
cookielawinfo-checkbox-functional	1 year	The cookie is set by the GDPR Cookie Consent plugin to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Necessary" category .
cookielawinfo-checkbox-others	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Others".
cookielawinfo-checkbox-performance	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to store the user consent for cookies in the category "Performance".

Cookie	Duration	Description
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt.innertube::nextId	never	This cookie, set by YouTube, registers a unique ID to store data on what videos from YouTube the user has seen.
yt.innertube::requests	never	This cookie, set by YouTube, registers a unique ID to store data on what videos from YouTube the user has seen.

Cookie	Duration	Description
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_168675207_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.